Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Most systemic therapies have not been systematically investigated in moderate to severe childhood plaque psoriasis. Evidence on the efficacy and safety of systemic treatments is limited and therapeutic guidelines are lacking. Recently adalimumab, a fully human monoclonal antibody that binds tumor necrosis factor (TNF)- alpha, was investigated in childhood psoriasis. Adalimumab is licensed for many inflammatory conditions including chronic plaque psoriasis in adults. Areas covered: A randomized phase III study published provided favourable efficacy and safety data of adalimumab in childhood psoriasis. The active comparator was methotrexate. After 16 weeks of treatment, a PASI 75 score was achieved in 58% of patients within the adalimumab 0.8 mg/kg group compared with 32% of patients within the methotrexate group. Safety data gave no evidence of drug-related serious adverse events and no organ toxicity. This is the first randomised controlled study of either adalimumab or methotrexate in children and adolescents with psoriasis. Expert opinion: The aforementioned trial was the first to provide clinical data on adalimumab’s efficacy and safety in the short term when treating children and adolescents with psoriasis. Through the use of an active comparator, this study has opened the way for the future assessment of systemic therapies in children and adolescent with this condition.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalExpert Opinion on Biological Therapy
DOIs
Publication statusAccepted/In press - Aug 23 2017

Fingerprint

Psoriasis
Clinical Trials
Methotrexate
Safety
Therapeutics
Expert Testimony
Toxicity
Adalimumab
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Guidelines
Pharmaceutical Preparations

Keywords

  • adalimumab
  • adolescence
  • Childhood
  • psoriasis
  • TNF
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

@article{0278e06d07094b2090d2ed255b4c7d95,
title = "Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation",
abstract = "Introduction: Most systemic therapies have not been systematically investigated in moderate to severe childhood plaque psoriasis. Evidence on the efficacy and safety of systemic treatments is limited and therapeutic guidelines are lacking. Recently adalimumab, a fully human monoclonal antibody that binds tumor necrosis factor (TNF)- alpha, was investigated in childhood psoriasis. Adalimumab is licensed for many inflammatory conditions including chronic plaque psoriasis in adults. Areas covered: A randomized phase III study published provided favourable efficacy and safety data of adalimumab in childhood psoriasis. The active comparator was methotrexate. After 16 weeks of treatment, a PASI 75 score was achieved in 58{\%} of patients within the adalimumab 0.8 mg/kg group compared with 32{\%} of patients within the methotrexate group. Safety data gave no evidence of drug-related serious adverse events and no organ toxicity. This is the first randomised controlled study of either adalimumab or methotrexate in children and adolescents with psoriasis. Expert opinion: The aforementioned trial was the first to provide clinical data on adalimumab’s efficacy and safety in the short term when treating children and adolescents with psoriasis. Through the use of an active comparator, this study has opened the way for the future assessment of systemic therapies in children and adolescent with this condition.",
keywords = "adalimumab, adolescence, Childhood, psoriasis, TNF, treatment",
author = "{Di Lernia}, Vito",
year = "2017",
month = "8",
day = "23",
doi = "10.1080/14712598.2017.1369950",
language = "English",
pages = "1--4",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Adalimumab for treating childhood plaque psoriasis

T2 - a clinical trial evaluation

AU - Di Lernia, Vito

PY - 2017/8/23

Y1 - 2017/8/23

N2 - Introduction: Most systemic therapies have not been systematically investigated in moderate to severe childhood plaque psoriasis. Evidence on the efficacy and safety of systemic treatments is limited and therapeutic guidelines are lacking. Recently adalimumab, a fully human monoclonal antibody that binds tumor necrosis factor (TNF)- alpha, was investigated in childhood psoriasis. Adalimumab is licensed for many inflammatory conditions including chronic plaque psoriasis in adults. Areas covered: A randomized phase III study published provided favourable efficacy and safety data of adalimumab in childhood psoriasis. The active comparator was methotrexate. After 16 weeks of treatment, a PASI 75 score was achieved in 58% of patients within the adalimumab 0.8 mg/kg group compared with 32% of patients within the methotrexate group. Safety data gave no evidence of drug-related serious adverse events and no organ toxicity. This is the first randomised controlled study of either adalimumab or methotrexate in children and adolescents with psoriasis. Expert opinion: The aforementioned trial was the first to provide clinical data on adalimumab’s efficacy and safety in the short term when treating children and adolescents with psoriasis. Through the use of an active comparator, this study has opened the way for the future assessment of systemic therapies in children and adolescent with this condition.

AB - Introduction: Most systemic therapies have not been systematically investigated in moderate to severe childhood plaque psoriasis. Evidence on the efficacy and safety of systemic treatments is limited and therapeutic guidelines are lacking. Recently adalimumab, a fully human monoclonal antibody that binds tumor necrosis factor (TNF)- alpha, was investigated in childhood psoriasis. Adalimumab is licensed for many inflammatory conditions including chronic plaque psoriasis in adults. Areas covered: A randomized phase III study published provided favourable efficacy and safety data of adalimumab in childhood psoriasis. The active comparator was methotrexate. After 16 weeks of treatment, a PASI 75 score was achieved in 58% of patients within the adalimumab 0.8 mg/kg group compared with 32% of patients within the methotrexate group. Safety data gave no evidence of drug-related serious adverse events and no organ toxicity. This is the first randomised controlled study of either adalimumab or methotrexate in children and adolescents with psoriasis. Expert opinion: The aforementioned trial was the first to provide clinical data on adalimumab’s efficacy and safety in the short term when treating children and adolescents with psoriasis. Through the use of an active comparator, this study has opened the way for the future assessment of systemic therapies in children and adolescent with this condition.

KW - adalimumab

KW - adolescence

KW - Childhood

KW - psoriasis

KW - TNF

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85028522179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028522179&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1369950

DO - 10.1080/14712598.2017.1369950

M3 - Article

AN - SCOPUS:85028522179

SP - 1

EP - 4

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -